Sign In
Buy YMAB
$8.61
+0 (+0%)
At Close: Dec 15, 2025
New Strong Buy Stocks for April 17th
08:30am, Wednesday, 17'th Apr 2024
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
10:56am, Thursday, 28'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable,
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
08:40am, Wednesday, 20'th Mar 2024
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price inc
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
09:05am, Thursday, 14'th Mar 2024
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and c
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
10:55am, Tuesday, 12'th Mar 2024
The consensus price target hints at a 31.4% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
01:01pm, Tuesday, 05'th Mar 2024
Does Y-mAbs Therapeutics, Inc. (YMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
07:30am, Monday, 04'th Mar 2024
Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript
10:33am, Friday, 01'st Mar 2024
Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
06:26pm, Thursday, 29'th Feb 2024
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.03 per share a year ago.
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
04:05pm, Thursday, 29'th Feb 2024
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
11:05am, Thursday, 22'nd Feb 2024
Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
07:30am, Friday, 16'th Feb 2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and f
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
05:11am, Tuesday, 13'th Feb 2024
Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 02'nd Jan 2024
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
04:05pm, Wednesday, 13'th Dec 2023
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co
